ServiceUpdated on 9 September 2025
Platform development services
Operations and Programme Manager at University of Twente at University of Twente
Enschede, Netherlands
About
At Bio/MicroSystems Centre we develop organ-on-chip platforms with a focus on interoperability, standardisation and modularity. Our expertise with validated modular components helps you rapidly test new applications and our experience with scaleable manufacturing can help you mass-produce the final platform.
We can help you:
-
Rapidly develop your technology towards new applications
-
Test and integrate key microphysiological systems
-
Standardize and validate your existing technology
-
Translate innovations from prototype to scalable solutions
Bio/MicroSystems Centre not only offers unique and innovative solutions, but also the knowledge and expertise to help adapt them to your needs. We can support the design of new microfluidic-enabled devices, integrate our in-house biological models, and help with standardised testing according to your target specifications.
Type
- Development
- Consulting
- Manufacturing
Applies to
- Innovative therapies - Microbiome therapy
- Innovative human-based test models - 2D & 3D in vitro cell culture models
- Innovative human-based test models - 3D spheroids
- Innovative human-based test models - Organ-on-Chip
- Development stages and support fuctions - Early discovery / basic research
- Development stages and support fuctions - Technology development and validation
- Development stages and support fuctions - Pre-clinical research and development
- Development stages and support fuctions - Contract research (CRO / CRMO)
- High Tech Systems & Materials - Chip design
Organisation
Similar opportunities
Product
EDDI - Epigenetic Digital Data Interface
- Innovative therapies - RNA therapy
- Innovative therapies - Gene therapy
- Innovative therapies - Gene editing
- Innovative therapies - Nanomedicine
- Innovative therapies - Stem cell therapy
- Innovative therapies - Oncolytic viruses
- Innovative therapies - Microbiome therapy
- Innovative therapies - Precision medicine
- Innovative therapies - Immune cell therapy
- Innovative therapies - Somatic cell therapy
- Innovative therapies - Tissue engineered products
- Innovative human-based test models - 3D spheroids
- Innovative human-based test models - 3D spheroids
- Innovative human-based test models - Organ-on-Chip
- Innovative human-based test models - In silico human models
- Development stages and support fuctions - Regulatory and compliance
- Innovative human-based test models - Bioprinted tissues and constructs
- Development stages and support fuctions - Data management and analytics
- Innovative human-based test models - Assembloids and multi-tissue models
- Development stages and support fuctions - Contract research (CRO / CRMO)
- Innovative human-based test models - 2D & 3D in vitro cell culture models
- Development stages and support fuctions - Early discovery / basic research
- Development stages and support fuctions - Funding, capital and investments
- Development stages and support fuctions - Ethics and social responsibility
- Development stages and support fuctions - Clinical research and development
- Development stages and support fuctions - Development and (GMP) manufacturing
- Development stages and support fuctions - Technology development and validation
- Development stages and support fuctions - Pre-clinical research and development
- Development stages and support fuctions - Commercial strategy and market access
daniel lüscher
CEO at QBDC GmbH
Nusshof, Switzerland
Service
- Innovative therapies - RNA therapy
- Innovative therapies - Gene therapy
- Innovative therapies - Nanomedicine
- Innovative therapies - Precision medicine
- Innovative therapies - Immune cell therapy
- Innovative human-based test models - 3D spheroids
- Innovative human-based test models - 3D spheroids
- Innovative human-based test models - Organ-on-Chip
- Innovative human-based test models - In silico human models
- Innovative human-based test models - Bioprinted tissues and constructs
- Innovative human-based test models - Assembloids and multi-tissue models
- Development stages and support fuctions - Contract research (CRO / CRMO)
- Innovative human-based test models - 2D & 3D in vitro cell culture models
- Development stages and support fuctions - Early discovery / basic research
- Development stages and support fuctions - Technology development and validation
- Development stages and support fuctions - Pre-clinical research and development
Monique van Scherpenzeel
CEO and founder at GlycoMScan B.V.
Arnhem, Netherlands
Service
- Consulting
- Development
- Innovative therapies - Precision medicine
- Innovative therapies - Immune cell therapy
- Innovative human-based test models - 3D spheroids
- Innovative human-based test models - 2D & 3D in vitro cell culture models
- Development stages and support fuctions - Early discovery / basic research
- Development stages and support fuctions - Technology development and validation
- Development stages and support fuctions - Pre-clinical research and development
Guido Zaman
Managing Director at Oncolines B.V.
Oss, Netherlands